A large-scale study conducted by scientists from America established a link between starting to take glucagon-like peptide-1 receptor agonists and a reduced likelihood of admission to a psychiatric hospital among individuals suffering from schizophrenia.
It was noted that drugs of this class demonstrated the most pronounced positive effect compared to other agents used for blood sugar control.
The results of this work were officially published in the scientific journal The Lancet Psychiatry.